Xueming Wu1, Niranjan Balu2, Wen Li1, Yong Chen1, Xin Yu1, Chun Yuan2, Zheng-Rong Lu1
1Biomedical Engineering, Case Western Reserve University, Cleveland, OH, United States; 2Department of Radiology, University of Washington, Seatle, WA, United States
This study designed, synthesized and evaluated a peptide-based low molecular weight MRI contrast agent specific to clotted plasma proteins for molecular imaging of atherosclerotic plaques with MRI. The atherosclerotic plaque imaging effectiveness of the targeted agent was demonstrated by using an atherosclerotic apolipoprotein Edeficient mouse model. Our preliminary results demonstrate that the newly developed targeted MRI contrast agent is promising for noninvasive assessment of plaque progression in an atherosclerotic mouse model.